Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review

Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors

(2014) Pasi A. Jänne et al.   Journal of Thoracic Oncology

Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib

(2014) N. Wagle et al.   Cancer Discovery

Phase II study of everolimus in metastatic urothelial cancer

(2013) Matthew I. Milowsky et al.   BJU INTERNATIONAL

Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial

(2013) N Colombo et al.   BRITISH JOURNAL OF CANCER

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer

(2013) K Kruczek et al.   BRITISH JOURNAL OF CANCER

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

(2013) K. Ng et al.   CLINICAL CANCER RESEARCH

A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer

(2013) Andrew J. Armstrong et al.   Clinical Genitourinary Cancer

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)

(2013) A.V. Tinker et al.   GYNECOLOGIC ONCOLOGY

Multicenter phase II study of everolimus in patients with metastatic or recurrent bone and soft-tissue sarcomas after failure of anthracycline and ifosfamide

(2013) Changhoon Yoo et al.   INVESTIGATIONAL NEW DRUGS

Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy

(2013) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2013) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

(2013) Gary K Schwartz et al.   LANCET ONCOLOGY

A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma

(2013) Julie E. Bauman et al.   ORAL ONCOLOGY

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

(2012) E. Seront et al.   ANNALS OF ONCOLOGY

Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma

(2012) Thomas Decaens et al.   DIGESTIVE AND LIVER DISEASE

Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma

(2012) Scott M. Schuetze et al.   EUROPEAN JOURNAL OF CANCER

Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study

(2012) Thanyanan Reungwetwattana et al.   Journal of Thoracic Oncology

Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma

(2011) Philipp Baumann et al.   ANTI-CANCER DRUGS

Blocking the mTOR pathway: a drug discovery perspective

(2011) Carlos Garcia-Echeverria   BIOCHEMICAL SOCIETY TRANSACTIONS

A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas

(2011) Scott Okuno et al.   CANCER

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

(2011) Amit M. Oza et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas

(2011) Sant P. Chawla et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer

(2011) Daniel P. Sutherlin et al.   JOURNAL OF MEDICINAL CHEMISTRY

PF-04691502, a Potent and Selective Oral Inhibitor of PI3K and mTOR Kinases with Antitumor Activity

(2011) J. Yuan et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin

(2011) S. V. Bhagwat et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer

(2011) I. Altomare et al.   ONCOLOGIST

Bevacizumab and everolimus in the treatment of patients with metastatic melanoma

(2010) John D. Hainsworth et al.   CANCER

A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma

(2010) Brian M. Slomovitz et al.   CANCER

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer

(2010) A. Tarhini et al.   CLINICAL CANCER RESEARCH

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer

(2010) Toshihiko Doi et al.   JOURNAL OF CLINICAL ONCOLOGY

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound26(PKI-587), a Highly Efficacious Dual Inhibitor

(2010) Aranapakam M. Venkatesan et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer

(2010) Katharine A. Price et al.   Journal of Thoracic Oncology

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

(2010) Darcy A. Krueger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin

(2010) Steven D. Knight et al.   ACS Medicinal Chemistry Letters

Response to imatinib plus sirolimus in advanced chordoma

(2009) S. Stacchiotti et al.   ANNALS OF ONCOLOGY

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

mTOR and cancer: many loops in one pathway

(2009) Alejo Efeyan et al.   CURRENT OPINION IN CELL BIOLOGY

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

(2009) RuiRong Yuan et al.   Journal of Hematology & Oncology

Targeting the phosphoinositide 3-kinase pathway in cancer

(2009) Pixu Liu et al.   NATURE REVIEWS DRUG DISCOVERY

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

(2008) J. R. Garlich et al.   CANCER RESEARCH

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

(2008) Magnus Rizell et al.   International Journal of Clinical Oncology

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

FBXW7 Targets mTOR for Degradation and Cooperates with PTEN in Tumor Suppression

(2008) Jian-Hua Mao et al.   SCIENCE